NDANASALSPRAY
Approved
Oct 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TYRVAYA (varenicline) is a nasal spray approved in October 2021 for dry eye disease, representing a novel non-systemic approach to treating aqueous tear deficiency. The drug works as a selective nicotinic acetylcholine receptor agonist delivered intranasally to stimulate tear production. This innovative delivery route differentiates it from traditional topical eye drops.
$0.037BPart D
Peak9.1 years to LOEProduct is in peak commercial phase with established Part D utilization, suggesting stable commercial teams and field infrastructure supporting ongoing market penetration.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
RP-008 in Combination With Daily Oral Varenicline for the Treatment of Trigeminal Neuralgia
Started Aug 2026
24 enrolled
Trigeminal Neuralgia
Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg
Started Jul 2026
50 enrolled
Dry Eye
Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation
Started Apr 2025
150 enrolled
Tobacco
Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)
Started Jan 2020
34 enrolled
Smoking Cessation
Deep rTMS and Varenicline for Smoking Cessation
Started Aug 2019
50 enrolled
Tobacco Use DisorderSmoking Cessation
Worked on TYRVAYA at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.